U.O. Endoscopia Digestiva, Fondazione Poliambulanza - Istituto Ospedaliero, Brescia, Italy.
Divisione Di Endoscopia, Istituto Europeo Di Oncologia, IRCCS, Milan, Italy.
Eur J Clin Pharmacol. 2022 Dec;78(12):1991-2002. doi: 10.1007/s00228-022-03405-z. Epub 2022 Oct 26.
Successful bowel preparation (BP) for colonoscopy depends on the instructions, diet, the laxative product, and patient adherence, which all affect colonoscopy quality. Nevertheless, there are no laxatives which combine effectiveness, safety, easy self-administration, good patient acceptance, and low cost. However, mannitol, a sugar alcohol, could be an attractive candidate for use in clinical practice if it is shown to demonstrate adequate efficacy and safety.
The present phase II dose-finding study compared three doses of mannitol (50, 100, and 150 g) to identify the best dose to be used in a subsequent phase III study.
The Boston Bowel Preparation Scale, caecal intubation rate, adherence, acceptability, and safety profile, including measurement of potentially dangerous colonic gas concentrations (CH, H, O), were considered in all patients. A weighted algorithm was used to identify the best mannitol dose for use in the subsequent study.
The per-protocol population included 60 patients in the 50 g group, 54 in the 100 g group, and 49 in the 150 g group. The 100 g dose was the best as it afforded optimal colon cleansing efficacy (94.4% of patients had adequate BP), adherence, acceptability, and safety, including negligible gas concentrations.
The present study demonstrated that the colon cleansing efficacy and safety of mannitol were dose dependent. Conversely, gas concentrations were not dose dependent and negligible in all patients. Combined evaluation of efficacy, tolerability, and safety, using a weighted algorithm, determined that mannitol 100 g was the best dose for the phase III study.
结肠镜检查的成功肠道准备(BP)取决于医嘱、饮食、泻药产品和患者的依从性,这些因素都会影响结肠镜检查的质量。然而,目前还没有一种泻药能够同时兼具疗效、安全性、易于自行服用、患者接受度高和成本低等优点。然而,如果甘露醇(一种糖醇)能够证明其疗效和安全性足够,那么它可能成为一种有吸引力的临床应用候选药物。
本 II 期剂量探索研究比较了甘露醇的三种剂量(50、100 和 150 g),以确定后续 III 期研究中使用的最佳剂量。
所有患者均评估波士顿肠道准备量表评分、盲肠插管率、依从性、可接受性和安全性概况,包括测量潜在危险的结肠气体浓度(CH、H、O)。使用加权算法确定后续研究中使用的最佳甘露醇剂量。
符合方案人群包括 50 g 组 60 例、100 g 组 54 例和 150 g 组 49 例。100 g 剂量是最佳的,因为它提供了最佳的结肠清洁效果(94.4%的患者肠道准备充分)、依从性、可接受性和安全性,包括气体浓度可忽略不计。
本研究表明甘露醇的结肠清洁效果和安全性与剂量有关。相反,气体浓度与剂量无关,且所有患者的气体浓度均可忽略不计。使用加权算法综合评估疗效、耐受性和安全性,确定甘露醇 100 g 是 III 期研究的最佳剂量。